Subject category:
Strategy and General Management
Published by:
IBS Case Development Center
Length: 9 pages
Data source: Published sources
Share a link:
https://casecent.re/p/63061
Write a review
|
No reviews for this item
This product has not been used yet
Abstract
Until 2000-2001, the global pharmaceutical industry used to consider Novartis as a ''sleepy European giant'' but then it released Glivec, a therapeutic drug that established itself as one of the most successful cancer therapies. By the turn of the 21st century, while major pharma players globally were facing a crisis of patent expiry on key drugs and poor research results, Novartis had 10 new drug launches slated between 2000-2003, three times that of any of its competitors. It had a Strategic Alliances division, which by 2004 had signed over 320 collaborations, out of which 90 collaborations were with biotech companies and 230 with academic centres in 19 countries. Due to its innovative research strategies, Novartis was judged by Fortune, as the fourth- best pharmaceutical company in the world in 2004. The case study offers the scope to discuss how Novartis, under the leadership of Professor Paul Herrling, Head of Corporate Research, is making efforts to sustain its growth by leveraging on its globalised research strategy.
About
Abstract
Until 2000-2001, the global pharmaceutical industry used to consider Novartis as a ''sleepy European giant'' but then it released Glivec, a therapeutic drug that established itself as one of the most successful cancer therapies. By the turn of the 21st century, while major pharma players globally were facing a crisis of patent expiry on key drugs and poor research results, Novartis had 10 new drug launches slated between 2000-2003, three times that of any of its competitors. It had a Strategic Alliances division, which by 2004 had signed over 320 collaborations, out of which 90 collaborations were with biotech companies and 230 with academic centres in 19 countries. Due to its innovative research strategies, Novartis was judged by Fortune, as the fourth- best pharmaceutical company in the world in 2004. The case study offers the scope to discuss how Novartis, under the leadership of Professor Paul Herrling, Head of Corporate Research, is making efforts to sustain its growth by leveraging on its globalised research strategy.